Biogen’s Spinraza, Fosun-Kite’s Yescarta and a controversial Alzheimer’s drug: All you need to know about China’s new state coveragenews2021-12-03T13:23:49+00:00December 3rd, 2021|Fierce Pharma|
More growth on the way for CSL? Australian giant in talks to buy Vifor for $7.1B: reportnews2021-12-02T19:44:41+00:00December 2nd, 2021|Fierce Pharma|
Bristol Myers wrongfully denied exemption requests to COVID-19 vaccination policy, employees say in lawsuitnews2021-12-02T16:24:12+00:00December 2nd, 2021|Fierce Pharma|
Fast-growing Real Chemistry names new CEO to lead agency’s digital transformationnews2021-12-02T15:37:42+00:00December 2nd, 2021|Fierce Pharma|
Novartis CEO Narasimhan aims to surmount $9B patent cliff with 20 blockbuster launchesnews2021-12-02T15:25:20+00:00December 2nd, 2021|Fierce Pharma|
Amgen’s Otezla notches win in genital psoriasis, snagging possible edge against forthcoming BMS rivalnews2021-12-02T15:02:46+00:00December 2nd, 2021|Fierce Pharma|
Leucid Bio taps Lonza’s production expertise for a phase 1 CAR-T therapy trialnews2021-12-02T13:16:43+00:00December 2nd, 2021|Fierce Pharma|
Aspen Pharmacare, pursuing J&J vaccine license, aims to shore up local capacity and quash shot inequality in Africanews2021-12-02T12:59:49+00:00December 2nd, 2021|Fierce Pharma|
Fujifilm socks $530M into U.K. vaccine, gene therapy and microbial production, creating 350 jobsnews2021-12-01T21:45:14+00:00December 1st, 2021|Fierce Pharma|
Sanofi aims to double vaccine sales by 2030, citing RSV and flu market expansion as key driversnews2021-12-01T18:51:03+00:00December 1st, 2021|Fierce Pharma|
